LAS VEGAS, NV--(Marketwire - November 05, 2012) - Hemp, Inc.'s (PINKSHEETS: HEMP) (www.hemp.com) subsidiary Marijuana, Inc. announced today a 20-year agreement for the worldwide marketing rights to cannabinoid medicinals using a uniquely effective and safe delivery system. Rather than delivering through digestion or the lungs, the proprietary system uses sublingual delivery by way of a pleasant tasting lozenge.
THC is measured by adding the level of THC and THCA together. This leads to confusing results as the THCA is not as bio-available as the THC. The proprietary system used to develop the lozenges uses a completely natural decarboxylation process to convert more THCA into THC prior to lozenge formation. By using a natural process to transform more THCA into THC, the active ingredients are much more bio-available and begin to work faster and last longer.
The contract calls for exclusive worldwide marketing rights to their rapid onset products derived from cannabis or hemp and containing THC and/or CBD. The terms of exclusivity are for 3 years and rights to market non-exclusively continue for 20 years. Marketing efforts will begin in Canada.
The initial product rollout features a patent pending coconut oil based lozenge that has been tested in Canada, with results showing that the lozenges provide a rapid onset time. The lozenge enables a precise quantity dosage, which is the systemic delivery of drugs through the mucosal membrane lining the floor of the mouth, and is perhaps the most preferred method to patient and clinician alike.
President David Tobias stated, "We feel that the coconut based lozenge is a superior method of delivery. Governments shun inhalation, even vaporizing, and the side effects may not be noticed for 20 years. Edibles incur first pass effect and potential pre-system elimination in the GI tract, and many tinctures contain a significant amount of alcohol, which can be problematic for people with allergies or addiction problems and are not as concentrated as other forms of herbal extracts that are typically about 25 times more concentrated than an equivalent tincture. Furthermore, we can adjust the cannabinoid profile for our lozenges to provide a wide range of beneficial effects."
CEO Bruce Perlowin continued, "We are confident that our new lozenges represent the most acceptable and yet effective delivery system available, providing patients with safe, measured, doses of natural cannabis extracts. This is the product that will trump everything else in the emerging trillion dollar cannabis industry. Just the US pharmaceutical rights alone are expected to bring up to 800 million dollars."
HEMP, INC.'s TRIPLE BOTTOM LINE
CEO of Hemp, Inc., Bruce Perlowin, is positioning the company as a leader with a social and environmental mission at its core. In fact, he wanted to, consciously, found a business with non-financial goals that weren't an after-thought, but are part of its DNA.